Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

8.615 +0.025 (+0.29%)

Streaming Delayed Price Updated: 12:59 PM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 09, 2021

Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency...

Via Benzinga

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

November 09, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix: Q3 Earnings Insights ↗

November 08, 2021

Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

November 08, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

November 05, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

November 01, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

October 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

October 28, 2021

From Ocular Therapeutix

Via Business Wire

What 5 Analyst Ratings Have To Say About Ocular Therapeutix ↗

October 25, 2021

Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings...

Via Benzinga

How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More ↗

October 25, 2021

Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

October 25, 2021

Wells Fargo boosted Bank of America Corporation (NYSE:B...

Via Benzinga

55 Biggest Movers From Friday ↗

October 25, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 22, 2021

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million...

Via Benzinga

Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump ↗

October 22, 2021

Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53. The U.S. has the...

Via Benzinga

Topics Stocks

35 Stocks Moving In Friday's Mid-Day Session ↗

October 22, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated...

Via Benzinga

Here's Why Ocular Therapeutix Stock Is Sinking Today ↗

October 22, 2021

The company's experimental dry-eye treatment produced some disappointing clinical trial results.

Via The Motley Fool

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

October 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

October 18, 2021

Barclays reduced the price target for The Walt Disney Company (NYSE:

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 12, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...

Via Benzinga

Why Are Ocular Therapeutix Shares Trading Higher Today? ↗

October 11, 2021

The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 11, 2021

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

October 11, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

28 Stocks Moving In Monday's Mid-Day Session ↗

October 11, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

September 28, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

September 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

September 13, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 07, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.